Skip to content
Learn More

Resources

iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer

May 9, 2022

Preclinical Data Presented at Frontiers in Cancer Immunotherapy 2022 Shows Potent Antibody-Dependent Cellular Cytotoxicity with Afucosylated Plant-Made Molecule NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, announced today a poster presentation on IBIO–101, the Company’s …

Read More

iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants

May 2, 2022

Data Showing Greater Glycosylation Homogeneity with the FastPharming® System Compared to Traditional Methods to be Presented at PEGS Conference & Expo BOSTON, May 02, 2022 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, announced today that it will present a poster …

Read More

iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease

January 26, 2022

– IBIO-202 Designed to Address Unmet Needs for Durability, Access, and Variant-inclusion – BRYAN, Texas, Jan. 26, 2022 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today shared an update on its lead COVID-19 vaccine program, IBIO-202. iBio recently received …

Read More

Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202

November 29, 2021

BRYAN, Texas, Nov. 29, 2021 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announced an update for its lead COVID-19 vaccine program, IBIO-202, in light of the emergence of the Omicron (B.1.1.529) variant of SARS-CoV-2.

Read More

iBio Announces Collaboration with UT Southwestern to Investigate IBIO-100 in Solid Tumors

November 15, 2021

BRYAN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) — iBio, Inc., a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announced a research collaboration with the University of Texas Southwestern Medical Center (“UT Southwestern”) to explore in solid tumors the anti-cancer potential of the molecule that is part of the IBIO-100 program.

Read More
Top